DNA hydrogels are biocompatible drug delivery systems for targeted therapeutic interventions. Conventional DNA hydrogels, formed with many DNA nanostructure units, lead to increased preparation costs ...

We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...

The NIH says funding cuts would save it billions of dollars a year. D.C.-area industry and academic leaders say it would cripple R&D.

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the latest effort by the biotech company to fill holes in its pipeline.Biogen will ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

Key Takeaways Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review ...

The biotech industry is on a stable growth path, owing to the integration of modern technologies and rapid drug discoveries.

Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...

Latigo Biotherapeutics, a non-opioid pain biotech looking to ride the waves created by Vertex Pharmaceuticals' pain drug ...

Jill Collins, CEO, Chief Strategy Officer, Audacity Health.

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein. Read why I'm ...